Ipsen
Clinical trials sponsored by Ipsen, explained in plain language.
Now part of
Ipsen S.A.
IPN
EURONEXT PARIS
A global biopharmaceutical company focused on oncology, neuroscience, and rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study analyzes Odevixibat's impact on rare liver disease outcomes Results expected Sep 2026 (estimated)
- New wrinkle injection shows promise in phase 3 trial Results expected Dec 2026 (estimated)
- New wrinkle treatment aims to smooth frown lines in large trial Results expected Dec 2026 (estimated)
- New hope for liver disease: drug shows promise in reducing damage Results expected Dec 2026 (estimated)
- New study tracks Real-World impact of arm spasticity treatment on caregivers Results expected Feb 2027 (estimated)